ABSTRACT BRCA1 inactivation is a frequent event in basal-like breast carcinomas (BLCs). However, BRCA1 can be inactivated by multiple mechanisms and determining its status is not a trivial issue. As an alternate approach, we profiled 65 BLC cases using SNP-arrays to define a signature of BRCA1-associated genomic instability. Large-scale state transitions (LST) defined as chromosomal break between adjacent regions of at least 10 Mb were found to be a robust indicator of BRCA1 status in this setting. Two major ploidy-specific cutoffs in LST distributions were sufficient to distinguish highly rearranged BLCs with 85% of proven
Introduction
Basal-like breast carcinomas (BLCs) are generally described as high-grade ductal carcinomas with a so-called triple-negative phenotype (absence of estrogen receptor [ER] , progesterone receptor [PR] and HER2/ERBB2 overexpression/amplification) and markers expressed by the normal basal/myoepithelial cells of the mammary gland (such as cytokeratins 5/6, 14, 17 and EGFR (for review, (1) ). The BLC entity partially overlaps with the larger triple-negative breast carcinoma (TNBC) disease (1) . The breast cancer susceptibility gene BRCA1 has a particular relationship to the basal-like phenotype. Firstly, BLCs represent the majority of breast carcinomas arising in BRCA1 mutation carriers, while representing less than 20% of sporadic breast tumors (2). Secondly, the high level of genomic instability observed in BLCs (3) (4) (5) fits BRCA1 involvement in double strand break (DSB) signaling and repair by homologous recombination (HR) (for review, (6) ). However, whether so-called BRCAness or HR deficiency is a general feature of BLCs (7) remains controversial, as BRCA1 inactivation (by mutation or methylation of BRCA1 promoter) is evidenced in less than 30% of BLC/TNBCs (8) , and a high level of genomic instability and response to treatment exploiting HR deficiency are inconsistently found in these tumors (9) (10) (11) (12) .
Considering its importance in diagnosis and treatment stratification, many studies have tried to define clinically relevant surrogate markers of BRCAness; for review, (13) . Genomic markers of BRCAness were searched for by comparing array-CGH profiles of BRCA1-mutated versus unselected hereditary or sporadic breast tumors (14) (15) (16) (17) . Studies comparing BLCs with or without BRCA1 inactivation either found no difference (10, 18, 19) or identified 3q gain as associated with BRCA1 inactivation (11) . A classifier based on array-CGH profiles and trained on BRCA1 mutated tumors within unselected group of tumors (20) showed a sensitivity of approximately 80% in TNBCs in two independent studies (21, 22) . The goal of this study was to identify genomic markers predicting actual BRCA1 inactivation within the group of BLCs. Analysis of SNP-array data using a specific data processing method (Genome Alteration Print, GAP) (23) identified ploidy and large-scale chromosomal breaks to be strongly predictive of the BRCA1 inactivation regardless of the mechanism of inactivation. Moreover, BRCA2 appeared mutated in a significant number of BLCs displaying similar features to BRCA1 inactivated cases, supporting the efficiency of these genomic markers in predicting the actual BRCA1 and BRCA2 status of these tumors. 
Methods

Patients and tumors
The experimental series consisted of 80 undifferentiated basal-like breast carcinomas (BLCs) from patients treated by first-line surgery at the Institut Curie (some BLCs have been described previously: GEO GSE18799 (23) (24) (25) (26) This research was approved by the institutional review boards of the Institut Curie. According to French regulations, patients were informed of the research performed using the biological specimens obtained during their treatment and did not express opposition. Germline BRCA1/2 gene analyses were performed exclusively in patients who attended a visit with a geneticist and a genetic counselor in a family cancer clinic, mostly at the Institut Curie, Paris, France and after informed consent.
Cell lines
The SNP array profiles were available for 17 basal-like cell lines (13 cell 
Methylation status of the BRCA1 promoter
Methylation of the BRCA1 promoter was assessed by methyl-specific PCR (MSP) after bisulfite conversion using the MethylDetector Kit (Active Motif, La Hulpe, Belgium), as described previously (24), with minor modifications (primer sequences are available upon request). 
BRCA1 mutation status
SNP-arrays
Genomic profiling was performed using two platforms: Illumina (32 cases; Human Hap300-Duo) and Affymetrix (48 cases; SNPChip6.0 array). Hybridization on the Illumina platform was performed by a service provider (Integragen, Evry, France); raw data files were processed by BeadStudio 3.3 (Illumina, reference model file HumanHap300v2_A); normalization was performed using the tQN algorithm (38). Hybridization on Affymetrix platform was performed at Institut Curie; cell files were processed by Genotyping Console 3.0.2 (Affymetrix, reference model file HapMap270, version 29).
Processing SNP arrays: Both Illumina and Affymetrix SNP array data were mined using the previously described and validated GAP method (23) to 8 copies and all segments exceeding 8-copy level were ascribed 8-copy status. Twenty-two possible segmental genotypes were therefore discriminated: A (1 copy); AA and AB (2 copies); AAA and AAB (3 copies); AAAA, AAAB, and AABB (4 copies); etc.
Chromosome number was estimated by the sum of the copy numbers detected at the pericentric regions (with an error rate less than 2 chromosomes per genome as assessed in 25 cell lines with known karyotype, see Supplementary Data, Table S1 ).
Number of breakpoints in each genomic profile was estimated based on the resulting interpretable copy number profile and after filtering smaller than 50 SNPs variations. locus was observed in 61 BLCs, including all BRCA1 and meBRCA1 BLCs. As previously described, 95% of the evaluated cases were found mutated for TP53 (41/43 BLCs; the two TP53 wild-type cases were BRCA1 BLCs) (24).
Near-diploidy in BLCs has a high positive predictive value for BRCA1 inactivation
In order to obtain insight into the specific genomic alterations of BLCs, genomic profiling was performed using SNP arrays, which provide two complementary measurements: copy number variation and allelic imbalance. The Genome Alteration Print (GAP) methodology for mining SNP arrays (23) Figure S8 ).
A two-step decision rule consistently detects BRCAness in BLCs
Based on the structural genomic features of BLCs described above, a two-step decision rule Figure S9 ).
The remaining 5 LST Hi BLCs were tested for the BRCA2 mutation and deleterious mutations were found in 3 cases (Supplementary data). With these findings, the sensitivity remained unchanged at 100% and the specificity was increased to 90% (including BRCA1 and BRCA2 tumors) in the experimental set of BLCs considered (overall accuracy 97%; p-value<10 -12 ,
Fisher's test) (Figure 3) .
A validation series of 55 BLC/TNBC (5 of the 60 samples were discarded due to low SNP array quality) included 15 cases with a BRCA1 germline mutation, 15 cases with BRCA1
promoter methylation, 1 case with a BRCA2 germline mutation, and 24 presumably non-BRCA1 cases. SNP array data were processed using the same workflow and structural genomic features were found globally similar to the experimental set ( Figure 3 , Supplementary Data, Table S5 ). Prediction of the BRCA1 inactivation displayed 100% sensitivity (all 30 BRCA1 and 1 BRCA2 inactivated cases were LST Hi ) and 54% specificity In order to test functionality of the homologous recombination pathway in the basal-like cell lines, formation of RAD51 foci was analyzed after ionizing radiation in 7 cell lines as a readout of HR pathway proficiency. As expected, no foci were observed in the 4 BRCA1-deficient cell lines. Interestingly, the 2 assessed LST Low cell lines displayed RAD51 foci accumulation, excluding undetected genetic or epigenetic BRCA1/2 inactivation in these cell lines ( Figure   4B ).
To estimate the stability of LSTs over time and replication, we compared SNP array profiles of primary breast tumors and their xenograft models, at early and late passages when available (28) . Number of LSTs displayed high intra-tumor stability, showing the LST number is an intrinsic property of the tumor, although with some variation with passages (Supplementary data, Table S7 and Figure S10 ). 
Discussion
In this study, we addressed prediction of BRCA1-inactivated status based on genomic features in the basal-like subtype of invasive ductal breast carcinomas (BLCs). Analysis of SNP array genomic profiles (23) of well characterized sets of BLCs identified two markers, tumor ploidy and number of Large-scale State Transitions (LSTs), which discriminated BRCA1/2-inactivated cases with high accuracy.
Our analysis of BLCs genomic profiles provided two novel findings. First, tumor genomes with near-diploid and near-tetraploid genomic contents also differed in terms of BRCA1 status: more than 80% of near-diploid tumor genomes were associated with BRCA1 inactivation (due to mutation or promoter methylation), whereas non-BRCA1 tumors had mostly near-tetraploid genomes. Second, the number of LSTs (chromosomal breaks between two adjacent regions of at least 10 Mb in size calculated after filtering of all variation less than 3 Mb in size) was introduced as a surrogate measure of a large scale genomic instability.
A prominent cutoff in the LST distribution was observed in each ploidy subgroup that distinguished highly rearranged genomes with a high proportion of proven BRCA1/2-inactivated BLCs from discriminatively less rearranged genomes without any proven BRCA1/2-inactivated BLCs. The nature of LSTs was clarified by matching them with rearrangements detected by complete genome sequencing of the same sample (36), and 2/3 of the LSTs were found corresponding to inter-chromosomal translocations.
A decision rule based on the ploidy-specific LST cutoffs correctly predicted all proven BRCA1-inactivated tumors in two independent series of BLCs (100% sensitivity). The discriminative power of LSTs was further reinforced by deleterious BRCA1 and BRCA2 mutations found in 10 of 12 LST Hi BLCs tested with no previous evidence of BRCA1 inactivation, whereas no mutation was detected in the LST Low BLCs tested (90% specificity). 
Two BRCA1 mutations were confirmed to be of somatic origin, further supporting the role of BRCA1 somatic mutations in breast carcinomas (8) . Our findings raise several questions. First, our analysis strongly suggests that BLCs actually include at least two different entities, differing in terms of their BRCA1/2 status. Interestingly, this dichotomy also exists in basal-like cellular models, in complete concordance with BRCA1/2 status and HR capacity. Further investigations will be required to determine whether these entities also differ in terms of oncogenic pathways. Second, the fact that BRCA1-deficient tumors are more frequently diploid than non-BRCA1 BLCs is rather intriguing, considering the numerous reports linking BRCA1 to centrosome structure and functions, and experimentally demonstrating aneuploidy and centrosome amplification as a consequence of BRCA1 inactivation (45). It is possible that near-tetraploid BRCA1-inactivated tumors are less frequently viable due to centrosome clustering dysfunction, multipolar division and cell death in this particular genetic context (46) . Alternatively, BRCA1-associated BLCs may have less selective advantages to undergo genome duplication than sporadic cases.
Inactivation of BRCA2 in six LST
Interestingly enough, genomic instability as measured by number of LSTs was similar in triple negative cell lines with a long history of cell division in vitro to that in primary tumors.
In the same line, numbers of LST were quite stable over passages in tumorgrafts, although some genomic changes were readily observed. A model which would account for these observations is that the instability induced by loss of BRCA1 or BRCA2 could be transient and 
